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The review article of treatments for castration-resistant prostate cancer (CRPC) 
by Sartor and Gillessen describes available sequencing data in detail with 
outlines of each agent.1 Currently, the efficacy of docetaxel, radium-223, 
sipuleucel-T, abiraterone, and enzalutamide (this is upcoming) as front-line 
agents and cabazitaxel, radium-223, abiraterone, and enzalutamide as 
post-docetaxel agents have been confirmed by phase III randomized controlled 
trials (RCT). While the development of treatment options should be of great 
benefit to CRPC patients, physicians may need to pay attention to patient 
selection for each treatment as these agents have not been compared with one 
another by head-to-head RCT. 
It is important to take into consideration that the eligibility criteria for each RCT 
were different. For example, the RCTs of radium-223, sipuleucel-T, and 
abiraterone did not include patients with visceral metastasis. Although these 
studies used the same primary endpoint, i.e., overall survival (OS), there were 
huge differences in OS even among control groups. Furthermore, the anti-tumor 
mechanisms of these agents are different. Docetaxel/cabazitaxel, radium-223, 
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and sipuleucel-T may be classified as chemotherapy, radiotherapy, and 
immunotherapy, respectively. As CRPC remains androgen receptor 
(AR)-dependent, abiraterone and enzalutamide target androgen/AR signaling 
and can be classified as hormone therapy. Both docetaxel and cabazitaxel are 
microtubular polymerization inhibitors. Nevertheless, cabazitaxel exerts its 
anti-tumor effect on post-docetaxel CRPC without obvious cross-resistance. 
Abiraterone is just an inhibitor of androgen biosynthesis. As it inhibits CYP17A1 
(both 17α-hydroxylase and 17,20-lyase), addition of prednisone is needed to 
compensate for the decrease in cortisol level.2 On the other hand, enzalutamide 
binds to the AR with greater relative affinity than the clinically used anti-androgen 
agent, bicalutamide, reduces the efficiency of its nuclear translocation, and 
impairs both DNA binding to androgen response elements and recruitment of 
co-activators.3 In terms of the mechanism, although there may be 
cross-resistance between these two hormonal therapies, enzalutamide seems to 
be superior to abiraterone. Actually, prostate-specific antigen response to 
sequential therapy from abiraterone to enzalutamide was much better than that 
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from enzalutamide to abiraterone. The another advantage of enzalutamide is that 
the RCT was terminated at the time of interim analysis due to its higher than 
expected efficacy. However, mechanisms of enzalutamide resistance in prostate 
cancer have been reported recently. 
As the anti-tumor effect of each single agent may be limited and there may be 
cross-resistance among agents, it is important to investigate better sequential 
treatment regimens. Unfortunately, few treatment sequence data are available, 
especially with more than two sequences or sequential treatment after 
radium-223 or sipuleucel-T. However, the review article by Sartor and Gillessen 
clearly shows the current available treatment sequencing data and helps 
physicians in practice to in treatment planning for CRPC. As the OS of advanced 
colorectal cancer patients improved with the availability of key agents in the 
course of treatment,4 the OS of CRPC patients may similarly be maximized with 
the availability of key agents. Planned sequential therapies such as those in 
kidney cancer may establish novel treatment strategies. Additional studies are 
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